Reply to Is progesterone a neutral or protective factor for breast cancer?

被引：0
|
作者：
Cathrin Brisken
机构：
[1] ISREC – Swiss Institute for Experimental Cancer Research,
[2] School of Life Sciences,undefined
[3] Ecole Polytechnique Fédérale de Lausanne (EPFL),undefined
来源：
Nature Reviews Cancer | 2014年 / 14卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：146 / 146
相关论文
共 50 条
  • [1] Reply to Is progesterone a neutral or protective factor for breast cancer?
    Brisken, Cathrin
    NATURE REVIEWS CANCER, 2014, 14 (02) : 146 - 146
  • [2] Is progesterone a neutral or protective factor for breast cancer?
    Paola Muti
    Nature Reviews Cancer, 2014, 14 : 146 - 146
  • [3] Is progesterone a neutral or protective factor for breast cancer?
    Muti, Paola
    NATURE REVIEWS CANCER, 2014, 14 (02) : 146 - 146
  • [4] Lifestyle, progesterone, and risk of breast cancer - Reply
    Jasienska, G
    Thune, I
    BMJ-BRITISH MEDICAL JOURNAL, 2001, 323 (7319): : 1002 - 1002B
  • [5] Insights into the role of progesterone receptors in breast cancer - Reply
    Olivotto, IA
    Bernstein, V
    Truong, PT
    Kelly, JS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) : 932 - 933
  • [6] It is not time to stop progesterone receptor testing in breast cancer - In reply
    Olivotto, IA
    Truong, PT
    Bernstein, V
    Kelly, JK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 3869 - 3870
  • [7] Introduction - Breast cancer prevention with estrogen and progesterone: Mimicking the protective effect of pregnancy
    Nandi, S
    Guzman, RC
    Yang, J
    Rajkumar, L
    Thordarson, G
    HORMONAL CARCINOGENESIS III, 2001, : 161 - 165
  • [8] Progesterone and breast cancer
    Lange, Carol A.
    Yee, Douglas
    WOMENS HEALTH, 2008, 4 (02) : 151 - 162
  • [9] Progesterone and Breast Cancer
    Trabert, Britton
    Sherman, Mark E.
    Kaman, Nagarajan
    Stanczyk, Frank Z.
    ENDOCRINE REVIEWS, 2020, 41 (02) : 320 - 344
  • [10] Time for reappraisal of progesterone-receptor testing in breast cancer management - Reply
    Banerjee, M
    Hryniuk, W
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) : 2871 - 2871
12345